| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8220107 | International Journal of Radiation Oncology*Biology*Physics | 2014 | 7 Pages |
Abstract
Local ablative therapy safely and durably eradicated sites of individual lesion progression in anaplastic lymphoma kinase-positive NSCLC patients receiving crizotinib. A dose-response relationship for local lesion control was observed. The suppression of OPD by LAT in patients taking crizotinib allowed an extended duration of exposure to crizotinib, which was associated with longer overall survival.
Related Topics
Physical Sciences and Engineering
Physics and Astronomy
Radiation
Authors
Gregory N. MD, PhD, Andrew J. MBBS, DMedSc, Benjamin MD, Robert C. MD, PhD, Laurie E. MD, MBA, Brian D. MD, MPH, D. Ross MD, PhD,